STREPSILS limun bez šećera 0.6 mg/1 Pastila, Lozenga+ 1.2 mg/1 Pastila, Lozenga pastila Bożnija Ħerżegovina - Kroat - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

strepsils limun bez šećera 0.6 mg/1 pastila, lozenga+ 1.2 mg/1 pastila, lozenga pastila

ataco d.o.o. mostar - od 2,4-dihlorbenzil алькохол, amilmetakrezol - pastila - 0.6 mg/1 pastila, lozenga+ 1.2 mg/1 pastila, lozenga - 1 pastila sadrži: 0,6 mg amilmetakrezola 1,2 mg 2,4dihlorbenzil alkohola

Claritine Alergija 1 mg/ml sirup Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

claritine alergija 1 mg/ml sirup

bayer d.o.o., radnička cesta 80, zagreb, hrvatska - loratadin - sirup - 1 mg/ml - urbroj: jedan ml sirupa sadrži 1 mg loratadina

Nurofen Forte za djecu 200 mg/5 ml oralna suspenzija s okusom jagode Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

nurofen forte za djecu 200 mg/5 ml oralna suspenzija s okusom jagode

reckitt benckiser d.o.o., ulica grada vukovara 269d, zagreb, hrvatska - ibuprofen - oralna suspenzija - 40 mg/ml - urbroj: svaki ml oralne suspenzije sadrži 40 mg ibuprofena

Xyzal 0,5 mg/ml oralna otopina Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

xyzal 0,5 mg/ml oralna otopina

ucb pharma s.a., allée de la recherche 60, anderlecht (bruxelles), belgija - levocetirizindiklorid - oralna otopina - 0,5 mg/ml - urbroj: 1 ml oralne otopine sadrži 0,5 mg levocetirizindiklorida

Vazkepa Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

vazkepa

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za modifikaciju lipida - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

PROSPAN 26mg Pastila - Kroat - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

prospan 26mg pastila

"salveo cg" d.o.o.- podgorica - bršljan (hedera helix), suvi ekstrakt lista - pastila - 26mg

IBUMAXRP 40mg/ml Oralna suspenzija - Kroat - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

ibumaxrp 40mg/ml oralna suspenzija

hemofarm a.d. vrŠac p.j. podgorica - ibuprofen - oralna suspenzija - 40mg/ml

Bronchostop Duo oralne gumaste pastile Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

bronchostop duo oralne gumaste pastile

kwizda pharma gmbh, effingergasse 21, beč, austrija - suhi ekstrakt timijanove zeleni (7-13:1), ekstrakcijsko otapalo: voda suhi ekstrakt korijena običnog bijelog sljeza (7-9:1), ekstrakcijsko otapalo: voda - oralna gumasta pastila - 51,1 mg + 4,5 mg - urbroj: jedna oralna gumasta pastila sadrži: 51,1 mg ekstrakta (kao suhi ekstrakt) iz thymus vulgaris l. and thymus zygis l., herba (timijanova zelen) (7-13:1) ekstrakcijsko otapalo: voda 4,5 mg ekstrakta (kao suhi ekstrakt) iz althaea officinalis l. (korijen običnog bijelog sljeza) (7-9:1) ekstrakcijsko otapalo: voda

Bisolvon 4 mg/5 ml sirup Kroazja - Kroat - HALMED (Agencija za lijekove i medicinske proizvode)

bisolvon 4 mg/5 ml sirup

opella healthcare france sas, 157 avenue charles de gaulle, neuilly-sur-seine, francuska - bromheksinklorid - sirup - 4 mg/5 ml - urbroj: 5 ml sirupa sadrži 4 mg bromheksinklorida

Imatinib Koanaa Unjoni Ewropea - Kroat - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - иматиниба мезилат - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacijenti koji imaju niske ili vrlo nizak rizik od recidiva, ne bi trebali primati adjuvantne terapije. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. osim po prvi put prijavljene kronične fazi kml, nema kontroliranih istraživanja pokazuju klinički učinak ili povećava stopu preživljavanja kod te bolesti.